|
Volcano Announces Activities at TCT 2014
Will Include Presentations on iFR, FFR, IVUS and SyncVision
|
 |
Walter E. Washington Convention Center |
September 12, 2014 -- The annual Transcatheter Cardiovascular Therapeutics meeting (TCT) starts this weekend in Washington, DC and runs through Wednesday, September 17. During that time many hundreds of presentations on the entire range of interventional procedures and devices will be offered to the 10,000 plus attendees.
While the main focus usually has been on devices such as drug-eluting stents, balloons, and transcatheter aortic valve replacements (TAVR), an area that has become increasingly important in recent years is that of functional measurement. The FAME and FAME 2 trials, along with many ancillary studies (several presented at the recent European Society of Cardiology meeting in Barcelona) have shown a definite benefit in utilizing fractional flow reserve (FFR) and similar modalities in the diagnostic phase and performance of percutaneous coronary interventions (PCI).
Volcano Corporation (Nasdaq: VOLC) has been a leader in this field, having recently gained FDA approval for its iFR modality. Volcano also is a leader in intravascular ultrasound imaging (IVUS). Both of these modalities have the ability to improve the performance of PCI, both in terms of decision-making (functional measurement can guide whether to stent or not) and accuracy (IVUS can guide the placement and sizing of the stent).
A complete agenda is available on Volcano's website for the key scientific events, live and edited cases, and "Meet the Experts" sessions.
An additional activity is what the company has dubbed, "The SyncVision VIP Experience": a private 30 minute hands-on demonstration of the SyncVision co-registration system. Registration for these sessions also is available on Volcano's website.
More information about SyncVision and iFR can be read in this morning's press release from Volcano Corporation:
Volcano to Showcase Two Novel Commercial Products at TCT 2014: SyncVision®, and the iFR® Modality
Release of these novel precision guidance tools will be demonstrated in live cases, symposia and training programs throughout the week
September 12, 2014 -- San Diego -- Volcano Corporation (NASDAQ: VOLC), a leading company focused on improving patient and economic outcomes on a global basis by developing and delivering innovative minimally invasive coronary and peripheral visualization, physiology diagnostics and therapies, announced today that it will be launching novel interventional precision guidance tools at the 27th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, being held in Washington, DC from September 13 to September 17.
Enhancing coronary imaging, the SyncVision® co-registration system will be shown at TCT for the first time since its Limited Market Release. SyncVision® features a live, on-line image processing workstation for coronary catheterizations that allows physicians to simultaneously navigate on both an angiogram and an IVUS image in a single correlated view. Attendees who visit the booth will experience hands-on how SyncVision® is designed to combine the functionality of the angiographic road map with the precision of the intra-vessel IVUS image. The product is currently installed in select institutions in the United States, Europe, Japan and China and will be featured in case demonstrations during the scientific sessions.
As a first for Volcano, the SyncVision® 'Angio Plus' suite of tools not only enhances the IVUS image, but augments the angiogram itself by offering image enhancement and stabilization tools. Physicians no longer have to use a Volcano IVUS catheter or pressure wire to augment the precision of the angiogram, enabling Volcano to offer value in significantly more cases.
The company also announces the full market release of its proprietary iFR® Modality in Meet the Expert sessions at its booth and live case transmissions. The iFR® Modality is a physiologic measurement performed using the same pressure wires and equipment utilized in cath labs for Fractional Flow Reserve (FFR), which avoids injection of hyperemic agents into the patient that can induce stress to the heart. This allows for a meaningful, lesion-specific assessment in seconds by amplifying the resting pressure waveform. The technology has been studied in over 4,000 patients, cleared by the FDA in March, 2014 and is now installed in over 700 hospitals in all major geographies.
"Volcano is the clear market leader in coronary imaging and physiology and will continue to be present for physicians and for patients, providing more precise tools to guide these important therapies," said Scott Huennekens, president and chief executive officer of Volcano Corp. "We believe the addition of the iFR® Modality and SyncVision® co-registration tools will allow us to add precision to everyday tools, with workflows that are fast and simple enough to be adopted in the busiest of cath labs. TCT is a great week for physicians and hospital team members to see these tools live for themselves and plan how to make them a part of their cath lab routine."
About Volcano Corporation
Through its multi-modality platform, Volcano Corporation is the global leader in intravascular imaging for coronary and peripheral applications, and physiology. The company also offers a suite of peripheral therapeutic devices. The company's broad range of technologies makes imaging and therapy simpler, more informative and less invasive and offers physicians and their patients around the world with industry-leading tools that aid diagnosis and guide and provide therapy. Founded in cardiovascular care and expanding into other specialties, Volcano is focused on improving patient and economic outcomes. For more information, visit the company's website at www.volcanocorp.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered "forward-looking statements." including statements regarding the potential benefits of the products and technologies described above. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause Volcano's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ include the pace and extent of market adoption of the company's products and technologies;; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; unexpected manufacturing issues; product introductions; unexpected new data, safety and technical issues; market conditions; and other risks inherent to medical device development and commercialization. These and additional risks and uncertainties are more fully described in Volcano's filings made with the Securities and Exchange Commission, including our recent quarterly report on Form 10-Q. Undue reliance should not be placed on forward-looking statements which speak only as of the date they are made. Volcano undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
Reported by Burt Cohen, September 12, 2014 (updated with press release)
|
